Vitrectomy, officially termed pars plana vitrectomy (PPV), is the foundational surgical intervention within the subspecialty of vitreoretinal surgery. The primary clinical objective of vitrectomy is to preserve or restore visual function by addressing pathological conditions affecting the posterior segment of the eye. The mechanism involves precise excision of the gel-like vitreous humour using a high-speed vitreous cutter, allowing the ophthalmic surgeon unobstructed mechanical and visual access to the retina—the light-sensitive layer lining the back of the eye. By removing opaque intraocular fluid, releasing vitreoretinal traction (pulling forces exerted by vitreous strands on retinal tissue), and stabilizing structural defects, vitrectomy re-establishes an anatomically sound ocular environment necessary for optimal light transmission and retinal signal processing.

Vitrectomy is performed in an ophthalmic operating theatre using an operating microscope. The eye is sterilized and anesthetized with retrobulbar local anesthesia or general anesthesia. Micro-incisional cannulas (23, 25, or 27 gauge) are inserted through the pars plana—a safe anatomical zone 3.5 to 4.0 millimeters behind the limbus containing no functional retina. An infusion line maintains constant intraocular pressure, an endoilluminator light pipe provides high-intensity visualization, and a pneumatic vitreous cutter operating at 5,000 to 10,000 cuts per minute excises vitreous strands. The surgeon clears vitreous gel, removes epiretinal scar tissue using micro-forceps, seals retinal breaks using an endolaser probe, and exchanges intraocular fluid with air, gas (SF6 or C3F8), or silicone oil tamponade. Incisions are self-sealing or secured with absorbable 10-0 vicryl sutures.

Vitrectomy provides clear, evidence-based structural and visual advantages for patients with posterior eye segment pathology, as confirmed by clinical guidelines from the American Academy of Ophthalmology (AAO) and the European Society of Retina Specialists (EURETINA):

• Anatomical Retinal Reattachment: Achieves high primary success rates (85% to 95%) in reattaching neurosensory retina in rhegmatogenous detached retina cases (AAO Retinal Detachment Preferred Practice Pattern, 2020).
• Restoration of Optical Clarity: Completely clears persistent non-clearing vitreous haemorrhage, restoring clear visual axes within days following blood clearance.
• Relief of Macular Traction: Relieves mechanical distortion in macular holes and epiretinal membranes, yielding anatomical closure rates above 90% for stage 2–4 macular holes (Jackson et al., 2013).
• Prevention of Progressive Vision Loss: Halts neurovascular proliferative cycles in severe diabetic eye disease through systematic endolaser application and tractional membrane dissection.
• Direct Infection and Inflammation Control: Rapidly reduces intraocular bacterial load and toxic inflammatory cytokines during acute endophthalmitis, improving visual preservation.

Recovery following vitrectomy occurs in distinct anatomical and functional phases over weeks to months:

• Days 1–3: Acute surgical inflammation phase. Expect mild discomfort, eyelid swelling, and visual blurriness. Strict adherence to face-down prone positioning (if gas or oil tamponade was placed) is mandatory for 16–20 hours per day as advised by the surgical team. Topical antibiotic and anti-inflammatory eye drops are applied 4 times daily.
• Weeks 1–2: Early healing phase. Surgical site discomfort resolves. If an expanding gas bubble was used, a distinct dark horizontal meniscus (line) will be visible in lower visual fields, shrinking gradually. Air or short-acting gas bubbles (SF6) begin significant reabsorption. Head positioning restrictions are typically relaxed based on 1-week scan results.
• Weeks 3–8: Tamponade reabsorption and tissue remodeling. Long-acting gas bubbles (C3F8) fully reabsorb over 6 to 8 weeks, replaced automatically by natural aqueous liquid. Visual acuity progressively improves as optical media clear, though final refractive correction requires glasses updates after total gas absorption.
• Months 3–6: Visual stabilization and late recovery. Macular microstructures undergo fine cellular reorganization. Patients evaluated for secondary cataract progression (a common physiological outcome in phakic eyes) and scheduled for silicone oil removal if long-term oil tamponade was used.

Vitrectomy is indicated for structural, vascular, and tractional pathologies of the posterior segment of the eye, including:

• Rhegmatogenous Retinal Detachment: Full-thickness tears in the retina allowing fluid accumulation beneath the neurosensory layer.
• Proliferative Diabetic Retinopathy: Non-clearing vitreous haemorrhage (bleeding into the eye gel) or tractional retinal detachment secondary to fibrovascular membrane formation.
• Epiretinal Membrane (Macular Pucker): A fine fibrous tissue growth over the macula causing visual distortion and reduced acuity.
• Idiopathic Macular Hole: A full-thickness defect in the central retina leading to a central scotoma (blind spot).
• Vitreous Opacities and Floaters: Dense persistent vitreous debris or asteroid hyalosis causing significant functional visual impairment.
• Severe Ocular Trauma: Penetrating eye injuries with intraocular foreign bodies or traumatic vitreoretinal disruption.
• Endophthalmitis: Severe intraocular bacterial or fungal infection requiring surgical debulking and direct intravitreal antibiotic delivery.

Pre-procedure preparation involves a comprehensive ophthalmic workup including visual acuity measurement, slit-lamp examination, dilated fundus examination, optical coherence tomography (OCT), and ocular ultrasound (B-scan) if media are opaque. Systemic medical history is reviewed, particularly blood pressure and diabetic glycemic control (HbA1c). Anticoagulant or antiplatelet medications are reviewed under physician guidance. On the day before and morning of surgery, prescribed prophylactic topical antibacterial drops may be initiated. Fasting for 6 to 8 hours is required if general anesthesia or intravenous sedation is planned. Patients must arrange transportation home and set up specialized face-down recovery cushions if post-operative gas positioning is anticipated.

Common and expected side effects include transient elevated intraocular pressure, ocular redness, mild eye aching, and accelerated nuclear sclerotic cataract formation in non-operated natural lenses (occurring in up to 80% of phakic patients within 2 years). Uncommon risks (1% to 5%) include recurrent vitreous hemorrhage, persistent macular edema, or baseline ocular hypertension. Rare but serious complications (less than 1%) comprise intraocular infection (endophthalmitis), severe retinal tears, rhegmatogenous retinal redetachment, suprachoroidal hemorrhage, and profound permanent loss of vision.

The clinical care pathway for vitrectomy encompasses four structured phases: pre-operative evaluation, intraoperative microsurgery, acute post-operative recovery, and long-term visual rehabilitation.

• Pre-Treatment Phase: Patients undergo a comprehensive ophthalmic baseline assessment, including optical coherence tomography (OCT) to image retinal microstructures, high-resolution ocular ultrasonography (B-scan) if vitreous opacity obscures the fundus, and systemic medical clearance. Informed consent and pre-operative anti-inflammatory eye drop regimes are initiated.
• Procedure Phase: Performed as a day-case procedure under local retrobulbar block with monitored sedation or general anaesthesia. Micro-incisional trocars (23-, 25-, or 27-gauge) are placed in the pars plana region. Gel excision, membrane peeling, laser photocoagulation, and intraocular tamponade (gas, air, or silicone oil) are completed within 45 to 90 minutes.
• Immediate Recovery Phase: Patients undergo monitoring in a post-anaesthesia care unit for 1 to 2 hours. Eye shields and topical antibiotic-steroid drops are applied. If an expandable gas bubble or silicone oil tamponade is utilized, strict prone positioning (face-down posture) is instructed for specific hours per day over 3 to 14 days.
• Follow-Up Phase: Clinical reviews occur at 24 hours, 1 week, 1 month, and 3 to 6 months post-operatively. Monitoring focuses on intraocular pressure, retinal reattachment integrity, structural healing via OCT, and progressive optical clearance as gas bubbles absorb or silicone oil is scheduled for removal.